Inflammation, autotoxicity and Alzheimer disease

Neurobiology of Aging

Volumn 22, Issue 6, 2001, Pages 799-809

  McGeer, Patrick L ^a   McGeer, Edith G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 2 MACROGLOBULIN; AMYLOID BETA PROTEIN; AMYLOID P COMPONENT; C REACTIVE PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INTERLEUKIN 1; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PENTRAXIN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ARTICLE; AUTOIMMUNITY; CELL CLONING; CLINICAL FEATURE; CLINICAL TRIAL; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNITY; INFLAMMATION; NERVE CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; STOMACH ULCER; TOXICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; AUTOIMMUNITY; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MICE; VACCINATION;

EID: 0035693924     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(01)00289-5     Document Type: Article

References (76)

1. A randomized controlled trial of prednisone in Alzheimer's disease
2. Alpha-2-macroglobulin is genetically associated with Alzheimer disease
3. Brain interleukin-1 beta in Alzheimer's disease and vascular dementia
4. Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: The NIMH Alzheimer disease genetics initiative
5. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer disease
6. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
7. Mice lacking both presenilin genes exhibit early embryonic patterning defects
8. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease
9. Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: Effects of ischemia and peripheral lipopolysaccharide administration
10. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease
11. Association of early-onset Alzheimer's disease with an interleukin-1α gene polymorphism
12. Presenilin-1 deficiency leads to loss of Cajal-Retzius neurons and cortical dysplasia similar to human type 2 lissencephaly
13. Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS
14. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease
15. Identification of the major A beta(1-42)-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition
16. Genetic effect of alpha-1-antichymotrypsin on the risk of Alzheimer disease
17. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men
18. Comparative analysis of Aβ chemical structure and amyloid plaque morphology of transgenic mice and Alzheimer disease brains
19. C-Reactive protein colocalized with complement in human heart during acute myocardial infarction
20. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?
21. Polymorphisms of the IL-6 gene increase the risk for late onset Alzheimer's disease and affect IL-6 plasma levels
22. Gene polymorphism affecting α1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk
23. Mice deficient in BACE1, Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation
24. Cyclooxygenase-2 inhibitors: Rationale and therapeutic potential for Alzheimer's disease
25. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR
26. Polymorphisms in inflammatory genes enhance the risk of Alzheimer disease
27. Autotoxicity and Alzheimer disease
28. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases
29. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiological studies
30. Membrane proteins that protect against complement lysis
31. C-reactive protein and outcome after ischemic stroke
32. Inflammation and Alzheimer's disease
33. Association of interleukin-1 gene polymorphisms with Alzheimer's disease
34. Localization of fractalkine and CX(3)CR1 mRNAs in rat brain - Does fractalkine play a role in signaling from neuron to microglia
35. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease
36. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment
37. Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates A-beta-1-42/41 expression
38. Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease
39. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease
40. Complement activation by β-amyloid in Alzheimer disease
41. Clinical trial of indomethacin in Alzheimer's disease
42. Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease
43. Results of a double-blind, placebo-controlled study of Celecoxib for the progression of Alzheimer's disease
44. Complement C1q is dramatically upregulated in brain microglia in response to transient global cerebral ischemia
45. A double-blind, placebo-controlled trial of diclofenac misoprostol in Alzheimer's disease
46. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
47. Selective accumulation of cyclooxygenase-1-expressing microglial cells/macrophages in lesions of human focal cerebral ischemia
48. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein
49. Risk of Alzheimer's disease and duration of NSAID use
50. Detection of complement alternative pathway mRNA and proteins in Alzheimer's disease brain
51. Induction of macrophage inflammatory protein MIP-1-alpha mRNA on glial cells after focal cerebral ischemia in the rat
52. Complement defense mechanisms
53. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries
54. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
55. Aβ-generating enzymes: Recent advances in β- and γ-secretase research
56. Duration of non-steroidal antiinflammatory drug use and risk of Alzheimer's disease. The Rotterdam study
57. Nitric oxide-releasing NSAIDs: A novel class of GI-sparing anti-inflammatory drugs
58. Complement interactions with amyloid β 1-42: A nidus for inflammation in AD brains
59. Antibody-mediated phagocytosis of the amyloid beta-peptide in nicroglia is differentially modulated by C1q
60. Multivalent binding of complement protein C1q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation
61. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease
62. Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q
63. Relative efficacies of amyloid beta peptide (Aβ) binding proteins in A beta aggregation
64. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity
65. Cytokine indices in Alzheimer's temporal cortex: No change in mature IL beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein
66. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease
67. Reduced neprilysin in high plaque areas of Alzheimer brain: A possible relationship to deficient degradation of β-amyloid peptide
68. Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease
69. Generation of C-reactive protein and complement components in atherosclerotic plaques
70. Human neurons generate C-reactive protein and amyloid P: Upregulation in Alzheimer's disease
71. Upregulated production and activation of the complement system in Alzheimer disease brain
72. Human heart generates complement proteins that are upregulated and activated after myocardial infarction
73. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs
74. Cyclooxygenase-1 in human Alzheimer and control brain: Quantitative analysis of expression in microglia and CA3 hippocampal neurons